N. Goldfinger

发表

Modulated expression of WFDC1 during carcinogenesis and cellular senescence

V. Rotter, S. Madar, R. Brosh, 2008, Carcinogenesis.

Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature

Shalom Madar, Ido Goldstein, Varda Rotter, 2012, Journal of Cell Science.

Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation.

V. Rotter, N. Goldfinger, P. Rehberger, 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

p53, a novel regulator of lipid metabolism pathways

Shalom Madar, Ido Goldstein, Varda Rotter, 2012, BMC Proceedings.

Falkor, a novel cell growth regulator isolated by a functional genetic screen

V. Rotter, N. Goldfinger, A. Gudkov, 2002, Oncogene.

Epithelial cells of different organs exhibit distinct patterns of p53-dependent and p53-independent apoptosis following DNA insult.

V. Rotter, N. Goldfinger, M. Memo, 1999, Experimental cell research.

Mice with reduced levels of p53 protein exhibit the testicular giant-cell degenerative syndrome.

V. Rotter, N. Goldfinger, L. Donehower, 1993, Proceedings of the National Academy of Sciences of the United States of America.

Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis

V. Rotter, G. Shaulsky, N. Goldfinger, 1990, Molecular and cellular biology.

Single chain antibody against the common epitope of mutant p53 restores wild‐type activity to mutant p53 protein

V. Rotter, N. Goldfinger, S. Orgad, 2005, FEBS letters.

Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.

Shalom Madar, Ido Goldstein, Varda Rotter, 2013, Carcinogenesis.

p53 is a regulator of macrophage differentiation

V. Rotter, L. Nissim, N. Goldfinger, 2004, Cell Death and Differentiation.

Change of the Death Pathway in Senescent Human Fibroblasts in Response to DNA Damage Is Caused by an Inability To Stabilize p53

V. Rotter, N. Goldfinger, A. Sigal, 2001, Molecular and Cellular Biology.

Association of Wild-Type P53 with Cell Differentiation: Induction of Pre-b Cell Maturation in Vitro

V. Rotter, G. Shaulsky, N. Goldfinger, 1993 .

Involvement of wild-type p53 protein in the cell cycle requires nuclear localization.

V. Rotter, G. Shaulsky, N. Goldfinger, 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins.

V. Rotter, G. Shaulsky, N. Goldfinger, 1991, Cancer research.

Amplification of the 20q Chromosomal Arm Occurs Early in Tumorigenic Transformation and May Initiate Cancer

V. Rotter, Y. Tabach, Y. Buganim, 2011, PloS one.

TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model

V. Rotter, S. Madar, R. Brosh, 2011, PloS one.

p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production

V. Rotter, E. Ruppin, S. Madar, 2013, Cancer & metabolism.

Does wild-type p53 play a role in normal cell differentiation?

V. Rotter, N. Goldfinger, D. Schwartz, 1994, Seminars in cancer biology.

Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts-Secreted Interferon Beta

V. Rotter, S. Madar, I. Goldstein, 2013, PloS one.

Identification of gene networks associated with erythroid differentiation.

V. Rotter, Y. Tabach, N. Goldfinger, 2009, Blood cells, molecules & diseases.

Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1.

V. Rotter, S. Madar, R. Brosh, 2009, Carcinogenesis.

p 53 Controls Low DNA Damage-dependent Premeiotic Checkpoint and Facilitates DNA Repair during Spermatogenesis 1

V. Rotter, N. Goldfinger, Z. Kam, 1999 .

p53 controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis.

V. Rotter, N. Goldfinger, Z. Kam, 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.

V. Rotter, N. Goldfinger, I. Zan‐Bar, 1993, Oncogene.

Mutant p53 attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species

V. Rotter, S. Madar, I. Goldstein, 2013 .

Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species

V. Rotter, S. Madar, I. Goldstein, 2012, Journal of Cell Science.

Expression of p53 in human leukemia and lymphoma.

V. Rotter, N. Goldfinger, D. Wolf, 1986, Blood.

Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule

V. Rotter, N. Goldfinger, D. Wolf, 1985 .

Nuclear localization is essential for the activity of p53 protein.

V. Rotter, G. Shaulsky, N. Goldfinger, 1991, Oncogene.

Altered Subcellular Localization of p53 in Estrogen-Dependent and Estrogen-Independent Breast Cancer Cells

V. Rotter, N. Goldfinger, Y. Sidi, 2002, Cancer investigation.

The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis

V. Rotter, N. Goldfinger, A. Sigal, 2001, Oncogene.

The Murine C (cid:57) -Terminally Alternatively Spliced Form of p53 Induces Attenuated Apoptosis in Myeloid Cells

V. Rotter, N. Goldfinger, D. Schwartz, 1997 .

Induction of Apoptosis and p53 Expression in Immature Thymocytes by Direct Interaction with Thymic Epithelial Cells

V. Rotter, N. Goldfinger, D. Schwartz, 1996, Scandinavian journal of immunology.

P53 gene mutation in a T-acute lymphoblastic leukemia cell line (loucy) with t(16:20) and 5q- chromosomal aberrations.

V. Rotter, N. Goldfinger, M. Prokocimer, 1998, Leukemia & lymphoma.

detoxifying enzymes and promotes the survival of cells with high ROS levels.

V. Rotter, S. Madar, H. Solomon, 2012 .

Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

V. Rotter, Y. Buganim, N. Goldfinger, 2007, Molecular and cellular biology.

Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension

V. Rotter, N. Goldfinger, N. Erez, 2007, Journal of hypertension.

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation

V. Rotter, Michal Sheffer, N. Goldfinger, 2014, Proceedings of the National Academy of Sciences.

The role of the C' terminus of murine p53 in the p53/mdm-2 regulatory loop.

V. Rotter, N. Goldfinger, N. Almog, 2001, Carcinogenesis.

Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes.

V. Rotter, N. Goldfinger, D. Schwartz, 1993, Oncogene.

Testicular tissue-specific expression of the p53 suppressor gene.

V. Rotter, N. Goldfinger, A. Levine, 1993, Developmental biology.

Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia

V. Rotter, N. Goldfinger, H. Karabulut, 1998, Genes, chromosomes & cancer.

Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype.

V. Rotter, Y. Tabach, N. Goldfinger, 2003, Cancer research.

Role of wild type p53 in the G2 phase: regulation of the γirradiation-induced delay and DNA repair

V. Rotter, N. Goldfinger, D. Schwartz, 1997, Oncogene.

The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts

V. Rotter, L. Nissim, N. Goldfinger, 2003, Oncogene.

Meth A fibrosarcoma cells express two transforming mutant p53 species.

Rotter, V. Rotter, G. Shaulsky, 1988, Oncogene.

Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.

V. Rotter, Y. Tabach, Y. Buganim, 2005, Cancer research.

Genetic Alterations in p 53 , INK 4 A , and HRas Genes along Defined Stages of Malignant Transformation

V. Rotter, Y. Tabach, Y. Buganim, 2005 .

The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA.

V. Rotter, N. Goldfinger, N. Erez, 2002, Carcinogenesis.

Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation

V. Rotter, I. Goldstein, H. Solomon, 2015, Cell Death and Differentiation.

p53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition

V. Rotter, S. Madar, R. Brosh, 2012, Cell Death and Differentiation.

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

V. Rotter, R. Brosh, O. Ezra, 2010, The Journal of experimental medicine.

Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues

Zohar Mukamel, Amos Tanay, Varda Rotter, 2012, Nature Genetics.

Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers

V. Rotter, H. Solomon, N. Goldfinger, 2018, Oncogene.

Genome-Wide Profiling of Histone H3 Lysine 4 and Lysine 27 Trimethylation Reveals an Epigenetic Signature in Prostate Carcinogenesis

Yi Qu, Inge Jonassen, Varda Rotter, 2009, PloS one.

hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.

V. Rotter, I. Kogan, N. Goldfinger, 2006, Cancer research.

Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells

V. Rotter, Y. Tabach, S. Madar, 2011, Cell Death and Differentiation.

p53 increases experimental metastatic capacity of murine carcinoma cells

V. Rotter, N. Goldfinger, V. Schirrmacher, 1988, Molecular and cellular biology.

Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule

V. Rotter, N. Goldfinger, D. Wolf, 1985, Molecular and cellular biology.

Amyloid-β precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress

V. Rotter, N. Goldfinger, M. Milyavsky, 2007, Oncogene.

Activated p53 suppresses the histone methyltransferase EZH2 gene

V. Rotter, N. Goldfinger, N. Erez, 2004, Oncogene.

Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation

V. Rotter, N. Goldfinger, K. Kalland, 2008, PloS one.

Cancer cells suppress p53 in adjacent fibroblasts

V. Rotter, N. Goldfinger, M. Papa, 2009, Oncogene.

Activation of p53 protein by telomeric (TTAGGG)n repeats.

V. Rotter, N. Goldfinger, I. Cohen, 2001, Nucleic acids research.

Regulation of AIF expression by p53

V. Rotter, N. Goldfinger, M. Oren, 2006, Cell Death and Differentiation.

Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels.

V. Rotter, N. Goldfinger, D. Schwartz, 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells

V. Rotter, N. Goldfinger, D. Schwartz, 1997, Molecular and cellular biology.

p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner

V. Rotter, N. Goldfinger, M. Pevsner-Fischer, 2008, PloS one.

A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.

V. Rotter, H. Solomon, N. Goldfinger, 2018, Cancer research.

The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele

D. Pe’er, V. Rotter, I. Goldstein, 2014, Cell Death and Differentiation.

Differential Influence of Normal and Cancer-Associated Fibroblasts on the Growth of Human Epithelial Cells in an In vitro Cocultivation Model of Prostate Cancer

V. Rotter, S. Madar, N. Goldfinger, 2009, Molecular Cancer Research.

p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53

V. Rotter, N. Goldfinger, N. Almog, 2000, Oncogene.

A Novel Translocation Breakpoint within the BPTF Gene Is Associated with a Pre-Malignant Phenotype

Shalom Madar, Ido Goldstein, Varda Rotter, 2010, PloS one.

p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation

Shalom Madar, Ido Goldstein, Varda Rotter, 2008, Molecular systems biology.

Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression.

V. Rotter, S. Madar, R. Brosh, 2011, Carcinogenesis.

Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress

V. Rotter, N. Goldfinger, D. Schwartz, 1999, Oncogene.

Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin.

V. Rotter, N. Goldfinger, D. Uberti, 1999, Brain research. Molecular brain research.

SPATA18, a Spermatogenesis-Associated Gene, Is a Novel Transcriptional Target of p53 and p63

V. Rotter, S. Madar, R. Brosh, 2011, Molecular and Cellular Biology.

Mutant p53 Attenuates the SMAD-Dependent Transforming Growth Factor β1 (TGF-β1) Signaling Pathway by Repressing the Expression of TGF-β Receptor Type II

V. Rotter, Y. Buganim, N. Goldfinger, 2007, Molecular and Cellular Biology.

Post-translational regulation of p53 function through 20S proteasome-mediated cleavage

V. Rotter, H. Solomon, N. Goldfinger, 2017, Cell Death and Differentiation.

Mutant p53 protein expression interferes with p53-independent apoptotic pathways

V. Rotter, N. Goldfinger, P. Sutphin, 1998, Oncogene.

Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function

V. Rotter, N. Goldfinger, M. Oren, 2004, Cancer Research.

Correction: Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

V. Rotter, N. Goldfinger, S. Pietrokovski, 2019, Oncotarget.

Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides

V. Rotter, N. Goldfinger, S. Pietrokovski, 2016, Oncotarget.

p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity

V. Rotter, Y. Buganim, O. Ezra, 2013, Cell Death and Differentiation.

Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner

V. Rotter, H. Solomon, N. Goldfinger, 2018, Cell Death & Disease.

p53‐dependent transcriptional regulation of EDA2R and its involvement in chemotherapy‐induced hair loss

V. Rotter, S. Madar, R. Brosh, 2010, FEBS letters.

p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress.

V. Rotter, N. Goldfinger, G. Banfalvi, 2001, Cancer research.

Modulates Base Excision Repair Activity in a Cell Cycle-specific Manner after Genotoxic Stress 1

V. Rotter, N. Goldfinger, G. Banfalvi, 2000 .

Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.

V. Rotter, R. Brosh, Y. Buganim, 2006, Cancer research.

Involvement of wild-type p53 in pre-B-cell differentiation in vitro.

V. Rotter, G. Shaulsky, N. Goldfinger, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy

V. Rotter, H. Solomon, N. Goldfinger, 2018, Cell Death & Differentiation.

p53, a novel regulator of lipid metabolism pathways.

V. Rotter, S. Madar, O. Ezra, 2012, Journal of hepatology.

Spot-1, a novel NLS-binding protein that interacts with p53 through a domain encoded by p(CA)n repeats.

V. Rotter, N. Goldfinger, N. B. Elkind, 1995, Oncogene.

Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth.

Varda Rotter, Igor Shats, Naomi Goldfinger, 2003, Cancer research.

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

V. Rotter, S. Madar, R. Brosh, 2010, Cancer research.

Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect.

V. Rotter, S. Madar, R. Brosh, 2007, Cancer cell.

Integrity of the N‐terminal transcription domain of p53 is required for mutant p53 interference with drug‐induced apoptosis

V. Rotter, N. Goldfinger, A. Sigal, 2001, The EMBO journal.

Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi‐directional loss of heterozygosity in bone marrow progenitors

V. Rotter, N. Goldfinger, A. Molchadsky, 2017, International journal of cancer.

Mutant p53-dependent mitochondrial metabolic alterations in a mesenchymal stem cell-based model of progressive malignancy

V. Rotter, H. Solomon, N. Goldfinger, 2018, Cell Death & Differentiation.

Expression of wild-type and mutant p53 proteins by recombinant vaccinia viruses

Varda Rotter, Dvora Ronen, Yael Teitz, 1992, Nucleic Acids Res..

Role of p 53 in Cancer Associated Gene Networks

Y. Tabach, H. Solomon, N. Goldfinger, 2008 .

Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner

V. Rotter, H. Solomon, N. Goldfinger, 2018, Cell Death & Disease.

Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation

V. Rotter, N. Goldfinger, K. Kalland, 2008, PloS one.

Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function

V. Rotter, N. Goldfinger, M. Oren, 2004, Cancer Research.

p53 Regulates the Ras circuit to inhibit the expression of a cancer-related gene signature by various molecular pathways.

R. Brosh, Y. Buganim, I. Goldstein, 2010, Cancer research.

Molecular and Cellular Pathobiology Cancer Research p 53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways

V. Rotter, R. Brosh, Y. Buganim, 2010 .

Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells

V. Rotter, R. Brosh, N. Goldfinger, 2010, The Journal of experimental medicine.